Current Report Filing (8-k)
February 16 2021 - 5:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 11, 2021
BIOANALYTICAL
SYSTEMS, INC.
(Exact name of registrant as specified in
its charter)
Indiana
|
|
0-23357
|
|
35-1345024
|
(State or other
jurisdiction of
incorporation or
organization)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
2701 Kent Avenue
West Lafayette, Indiana
|
47906-1382
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (765) 463-4527
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17CFR240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17CFR240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17CFR240.13e-4(c))
|
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbols
|
Name of exchange on which registered
|
Common Shares
|
BASi
|
NASDAQ Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 5.02 Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Effective as of February
15, 2021, the Board of Directors of Bioanalytical Systems, Inc. (the “Company”) elected John Gregory Beattie, age 54,
Chief Operating Officer of the Company.
Mr. Beattie previously held Corporate Vice
President positions at Charles River Laboratories, a contract research organization, where he led business units within all three
of their segments. In these roles, Mr. Beattie was responsible for driving operational performance. There are no arrangements
or understandings between Mr. Beattie and any other persons pursuant to which he was elected as an officer and Mr. Beattie has
no family relationships with any other director or executive officer of the Company.
Under the terms of
Mr. Beattie’s employment, he is entitled to receive an annual base salary of $300,000 and a discretionary annual incentive
bonus which is tied to company performance metrics and individual achievements. Mr. Beattie is also entitled to participate in
the Company’s benefit plans and programs provided to Company executives generally, subject to eligibility requirements and
the other terms and conditions of those plans and programs. On February 15, 2021, Mr. Beattie received a grant of 15,000 restricted
shares, which vest on the second anniversary of the grant date, subject to relevant vesting parameters.
Item 7.01 Regulation FD Disclosure.
On February 11, 2021,
the Company issued a press release regarding Mr. Beattie’s election. A copy of the press release is furnished as Exhibit
99.1 to this report. Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or
the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Bioanalytical Systems, Inc.
|
|
|
|
|
Date: February 16, 2021
|
By:
|
/s/ Beth A. Taylor
|
|
Beth A. Taylor
|
|
Chief Financial Officer, Vice President – Finance
|
|
|
|
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2023 to Apr 2024